Abstract
Context and Policy Issues:
The purpose of the CMII is to document current practices and developments in the supply, distribution, technical operations, and general clinical use of advanced imaging equipment across Canada. Medical imaging is a vital component of modern health care, playing a role in the diagnosis, staging, and monitoring of many diseases and conditions. As new medical imaging technologies become available and population needs change, it is important to keep track of where imaging capacity exists, how equipment is used, and the adoption of tools that may support appropriate imaging, system efficiencies, and wait-list reductions.
Methods:
CADTH collected data on six advanced imaging modalities: CT, MRI, PET-CT, single-photon emission computed tomography (SPECT), SPECT-CT, and PET-MRI using a web-based survey and a search of the literature. The data were reviewed by validators for accuracy and validators provided additional information of provincial and regional policies and practices.
Summary of Evidence:
Of the modalities surveyed, CT is the most widely distributed, with the highest number of units, followed by MRI. All provinces and territories have at least one CT unit; all provinces and Yukon have at least one MRI unit; and all provinces have at least one SPECT and/or SPECT-CT unit. None of the territories have SPECT or SPECT-CT. Nine provinces have PET-CT in clinical use. Two provinces, Alberta and Ontario, have PET-MRI that is used for research purposes.
Regarding the total volume of exams, CT is the most-used modality (5.41 million exams per year), followed by MRI (2.33 million exams per year), SPECT and SPECT-CT combined (1.2 million exams per year), and PET-CT (125,775 exams per year).
Each imaging modality, apart from SPECT, experienced growth in the last decade in Canada in the number of units and the number of units per million people. CT experienced the slowest growth rate of all imaging modalities — at a 1.4% increase in units per million people over the last decade — compared with other imaging modalities (MRI 20%; PET-CT 25%; and SPECT-CT 70%).
Over the last decade, the overall volume of exams increased by 32% and 62% for CT and MRI, respectively. Similarly, the number of exams per thousand population increased by 18% and 46%, respectively. Examination data for the other modalities were not available in 2010.
Conclusions and Implications for Decision or Policy-Making:
The CMII data provides insight into the current context of medical imaging across Canada and raise questions related to how medical imaging is monitored and regulated, and how it is optimally used. As well, the data raise questions about how funding structures are organized, what the most cost-effective practices are, and whether access is equitable, especially in rural and remote areas. Overall, the findings of this report may help decision-makers identify gaps in service; inform medical imaging-related strategic planning on a national, provincial, or territorial basis; and help anticipate future growth and need for replacement. Additionally, the data can be used to identify system efficiencies and monitor the adoption of practices and tools that may support appropriate imaging and wait-list reductions.
Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.
While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.
CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.
This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.
Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.
This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.
This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.
